The aim of this treatment was to destroy the CNV in order to preserve macular function; the success is strongly dependent on its ability to eradicate the CNV without destroying the fovea.

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Macular degeneration ... resulting in the growth of scar tissues that may detach the retina. When the retina becomes detached ...

Photodynamic therapy with verteporfin of CNV represents an advancement in the treatment of myopic macular degeneration ... or from an enlargement of laser scar resulting in absolute scotoma ...